Humacyte adds Scott Coward to board, names him to audit committee

By Public Technologies
  • Humacyte added Scott Coward and Paul Kuznik to its board as it expands the Symvess launch and prepares an ATEV dialysis-access launch.
  • Coward was EVP, chief legal officer, chief administrative officer, secretary at Exact Sciences from 2015-2022; later served on its board through March 2026.
  • He joined K&L Gates in July 2026; appointed to Humacyte’s audit committee.
  • Kuznik was CEO and a director at Bolton Medical from 2015-2018; later led Terumo Aortic’s US and North America units through 2023.
  • He was appointed to Humacyte’s commercial committee.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Humacyte Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609280800PRIMZONEFULLFEED9834407) on September 28, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.